1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012.
2. Clinical features of metastatic bone disease and risk of skeletal morbidity;RE Coleman;Clinical cancer research: an official journal of the American Association for Cancer Research,2006
3. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care;F Saad;European urology,2004
4. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer;KP Weinfurt;Annals of oncology: official journal of the European Society for Medical Oncology / ESMO,2005
5. The cost of treating skeletal-related events in patients with prostate cancer;MJ Lage;The American journal of managed care,2008